Ventyx Biosciences
VTYX
VTYX was delisted on the 3rd of March, 2026.
104 hedge funds and large institutions have $1.41B invested in Ventyx Biosciences in 2022 Q3 according to their latest regulatory filings, with 44 funds opening new positions, 29 increasing their positions, 20 reducing their positions, and 3 closing their positions.
1,367% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 3
245% more capital invested
Capital invested by funds: $408M → $1.41B (+$1B)
65% more funds holding
Funds holding: 63 → 104 (+41)
50% more funds holding in top 10
Funds holding in top 10: 4 → 6 (+2)
45% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 20
11.64% more ownership
Funds ownership: 68.1% → 79.74% (+12%)
12% less call options, than puts
Call options by funds: $1.97M | Put options by funds: $2.25M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
+$38.5M |
| 2 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
+$31M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
+$30.2M |
| 4 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$23.7M |
| 5 |
BC
Boxer Capital
San Diego,
California
|
+$18.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$23.6M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
-$20.3M |
| 3 |
EC
EcoR1 Capital
San Francisco,
California
|
-$19.9M |
| 4 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$19.1M |
| 5 |
VC
Vivo Capital
Palo Alto,
California
|
-$12.5M |
VTYX Hedge Fund Activity: Q3 2022 in Review
104 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in Ventyx Biosciences (VTYX) for Q3 2022, worth a combined $1.41B — up 245% from $408M a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new VTYX positions and 3 closed out — a net gain of 41 holders — while 29 added to existing stakes and 20 trimmed.
The largest buyer was Lord, Abbett & Co, opening a new position worth an estimated $38.5M. The largest seller was OrbiMed, cutting an estimated $23.6M.
- 104 institutional investors held Ventyx Biosciences (VTYX) as of Q3 2022, up from 63 in Q2 2022.
- Funds reported $1.41B of Ventyx Biosciences stock for Q3 2022, up 245% quarter-over-quarter.
- 44 funds opened new Ventyx Biosciences positions in Q3 2022 and 3 closed out, a net change of +41 holders.
- The largest Ventyx Biosciences buyer in Q3 2022 was Lord, Abbett & Co, an estimated $38.5M added.
- The largest Ventyx Biosciences seller in Q3 2022 was OrbiMed, an estimated $23.6M sold.
Based on aggregated 13F filings for Q3 2022.